2|0|Public
50|$|In {{addition}} to its activity as an aromatase inhibitor, <b>plomestane</b> has weak androgenic properties.|$|E
5000|$|<b>Plomestane</b> (INN, USAN; former {{developmental}} {{code name}} MDL-18,962; {{also known as}} propargylestrenedione, PED, and 10-propargylestr-4-ene-3,17-dione) is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent {{for the treatment of}} breast cancer. It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration. However, development of the drug for clinical use was halted due to [...] "technical issues" [...] and it was never marketed.|$|E

